NCPD Article

Antibody–Drug Conjugates and Ocular Toxicity: Nursing, Patient, and Organizational Implications for Care

Caroline Clark

Ikuko Komo

immunoconjugates, eye diseases, patient education, self-care
CJON 2024, 28(2), 188-196. DOI: 10.1188/24.CJON.188-196

Background: Antibody–drug conjugates (ADCs) are a novel class of drugs with rapidly expanding oncology indications across solid and hematologic malignancies.

Objectives: This article provides an overview of ADCs with a high risk of ocular reactions and guidance for oncology nurses to help mitigate risk and identify toxicities for prompt management.

Methods: This review presents updated evidence, manufacturer recommendations, and clinical guidance about three ADCs with a risk of overall ocular reactions exceeding 40%, as well as strategies to prepare patients for treatment, prevent reactions, and respond to presenting ocular toxicities.

Findings: ADCs can cause a range of ocular reactions from mild dry eye to severe and dose- limiting corneal adverse reactions and vision loss. Oncology nurses and other members of the interprofessional team can perform focused clinical assessment, provide patient education about self-management and prevention, and coordinate surrounding eye care for patients receiving treatment with ADCs.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.